Importantly, this study showed that 89% of individuals with mCRPC harbor a clinically actionable aberration, including 63% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations (Figure 2) [67]. The gene discussed is AR; the disease is cancer.